Efficacy of anti-CD3 monoclonal antibodies in delaying the progression of recent-onset type 1 diabetes mellitus: A systematic review, meta-analyses and meta-regression.
Muhammad Talal AshrafSyed Hassan Ahmed RizviMuhammad Arham Bin KashifMuhammad Khuzzaim Shakeel KhanSyed Hassan AhmedMuhammad Sohaib AsgharPublished in: Diabetes, obesity & metabolism (2023)
The findings of this review suggest that anti-CD3 monoclonal antibody treatment increases endogenous insulin production and improves the lifestyle of patients by reducing insulin dosage. Future studies should consider the limitations, including sample size, heterogeneity and duration of follow-up, to validate the generalizability of these findings further.
Keyphrases
- monoclonal antibody
- type diabetes
- meta analyses
- glycemic control
- end stage renal disease
- systematic review
- ejection fraction
- newly diagnosed
- metabolic syndrome
- chronic kidney disease
- prognostic factors
- cardiovascular disease
- peritoneal dialysis
- randomized controlled trial
- physical activity
- weight loss
- patient reported outcomes
- nk cells
- insulin resistance